These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 26439470)

  • 1. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.
    Esposito S; Principi N;
    Future Microbiol; 2015; 10(10):1599-607. PubMed ID: 26439470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumococcal serotype distribution in adults with invasive disease and in carrier children in Italy: Should we expect herd protection of adults through infants' vaccination?
    Azzari C; Cortimiglia M; Nieddu F; Moriondo M; Indolfi G; Mattei R; Zuliani M; Adriani B; Degl'Innocenti R; Consales G; Aquilini D; Bini G; Di Natale ME; Canessa C; Ricci S; de Vitis E; Mangone G; Bechini A; Bonanni P; Pasinato A; Resti M
    Hum Vaccin Immunother; 2016; 12(2):344-50. PubMed ID: 26647277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
    Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
    Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children.
    Esposito S; Principi N
    J Immunol Res; 2015; 2015():591580. PubMed ID: 26351648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up of serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae in child carriage after a PCV13-to-PCV10 vaccine switch in Belgium.
    Wouters I; Desmet S; Van Heirstraeten L; Blaizot S; Verhaegen J; Van Damme P; Malhotra-Kumar S; Theeten H;
    Vaccine; 2019 Feb; 37(8):1080-1086. PubMed ID: 30665775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
    Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
    J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
    Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
    Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014.
    Cohen R; Biscardi S; Levy C
    Hum Vaccin Immunother; 2016; 12(2):277-84. PubMed ID: 26905678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.
    Weil-Olivier C; van der Linden M; de Schutter I; Dagan R; Mantovani L
    BMC Infect Dis; 2012 Sep; 12():207. PubMed ID: 22954038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
    Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
    Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction.
    Gladstone RA; Jefferies JM; Tocheva AS; Beard KR; Garley D; Chong WW; Bentley SD; Faust SN; Clarke SC
    Vaccine; 2015 Apr; 33(17):2015-21. PubMed ID: 25776920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.
    Principi N; Esposito S
    Expert Rev Vaccines; 2015; 14(10):1359-66. PubMed ID: 26289973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nasopharyngeal carriage of individual Streptococcus pneumoniae serotypes during pediatric radiologically confirmed community acquired pneumonia following PCV7 introduction in Switzerland.
    Chappuy H; Keitel K; Gehri M; Tabin R; Robitaille L; Raymond F; Corbeil J; Maspoli V; Bouazza N; Alcoba G; Lacroix L; Manzano S; Galetto-Lacour A; Gervaix A
    BMC Infect Dis; 2013 Jul; 13():357. PubMed ID: 23899390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal carriage and serotype variation before and after introduction of pneumococcal conjugate vaccines in patients with acute otitis media in Switzerland.
    Allemann A; Frey PM; Brugger SD; Hilty M
    Vaccine; 2017 Apr; 35(15):1946-1953. PubMed ID: 28279564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era.
    Zuccotti G; Mameli C; Daprai L; Garlaschi ML; Dilillo D; Bedogni G; Faccini M; Gramegna M; Torresani E; ; Ballerini E; Benincaso A; Bonvissuto M; Bricalli D; Brioschi M; Calloni CS; Camiletti MI; Colella G; De Angelis L; Decarlis S; Di Nello F; Dozzi M; Galli E; Gandini V; Giuliani MG; Laviola F; Loda B; Macedoni M; Mazzucchi E; Metta MG; Moscatiello A; Nannini P; Petruzzi M; Picicco D; Picciotti M; Pisanelli S; Porta N; Ramponi G; Redaelli F; Rubini R; Sala N; Saitta V; Scelza G; Tiso RM; Tomasetto M; Torcoletti M; Travaini M; Valentini M; Vessia C
    Vaccine; 2014 Jan; 32(5):527-34. PubMed ID: 24342249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
    Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
    J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.